The Heparan Sulfate Binding Peptide in Tumor Progression of Triple-Negative Breast Cancer.
anti-angiogenic
breast cancer (BC)
breast neoplasia
glycosaminoglycans
phage display
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
04
2021
accepted:
29
06
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
24
8
2021
Statut:
epublish
Résumé
Angiogenesis is the formation of new vessels from pre-existing vasculature. The heparan sulfate chains from endothelial cell proteoglycans interact with the major angiogenic factors, regulating blood vessels´ formation. Since the FDA´s first approval, anti-angiogenic therapy has shown tumor progression inhibition and increased patient survival. Previous work in our group has selected an HS-binding peptide using a phage display system. Therefore, we investigated the effect of the selected peptide in angiogenesis and tumor progression. The HS-binding peptide showed a higher affinity for heparin N-sulfated. The HS-binding peptide was able to inhibit the proliferation of human endothelial umbilical cord cells (HUVEC) by modulation of FGF-2. It was verified a significant decrease in the tube formation of human endothelial cells and capillary formation of mice aorta treated with HS-binding peptide. HS-binding peptide also inhibited the formation of sub-intestinal blood vessels in zebrafish embryos. Additionally, in zebrafish embryos, the tumor size decreased after treatment with HS-binding peptide.
Identifiants
pubmed: 34422650
doi: 10.3389/fonc.2021.697626
pmc: PMC8372403
doi:
Types de publication
Journal Article
Langues
eng
Pagination
697626Informations de copyright
Copyright © 2021 Melo, Wang, Fujimura, Strnadel, Meneghetti, Nader, Klemke and Pinhal.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS One. 2010 Apr 01;5(4):e9945
pubmed: 20376344
Nat Rev Mol Cell Biol. 2006 May;7(5):359-71
pubmed: 16633338
J Biol Chem. 2011 Feb 18;286(7):5338-46
pubmed: 20129923
Science. 1998 Jan 16;279(5349):377-80
pubmed: 9430587
Nat Rev Mol Cell Biol. 2011 Aug 23;12(9):551-64
pubmed: 21860391
Biochem Biophys Res Commun. 1983 Mar 29;111(3):865-71
pubmed: 6220714
An Acad Bras Cienc. 2009 Sep;81(3):409-29
pubmed: 19722012
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
Prog Biophys Mol Biol. 2013 Nov;113(2):333-54
pubmed: 24139944
J Biol Chem. 2006 Jan 6;281(1):656-67
pubmed: 16263708
Nat Rev Cancer. 2010 Feb;10(2):116-29
pubmed: 20094046
Nature. 2005 Dec 15;438(7070):967-74
pubmed: 16355214
Angiogenesis. 2014 Jul;17(3):443-62
pubmed: 24146040
Protein Cell. 2019 Nov;10(11):787-807
pubmed: 31140150
Semin Cancer Biol. 2015 Dec;35:3-10
pubmed: 26416466
Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):215-66
pubmed: 25772309
Glycobiology. 2011 Sep;21(9):1194-205
pubmed: 21515908
Carbohydr Res. 1996 Nov 20;294:15-27
pubmed: 8962483
J Biol Chem. 2006 Jan 20;281(3):1731-40
pubmed: 16258170
Nature. 2007 Apr 26;446(7139):1030-7
pubmed: 17460664
Development. 2009 Sep;136(18):3143-52
pubmed: 19700618
Org Biomol Chem. 2017 Jul 21;15(27):5656-5668
pubmed: 28653068
Cold Spring Harb Perspect Biol. 2011 Jul 01;3(7):
pubmed: 21690215
J Biol Chem. 2000 May 5;275(18):13564-70
pubmed: 10788472
Mol Cell. 2000 Sep;6(3):743-50
pubmed: 11030354